Efavirenz induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir

被引：20

作者：

Duval, X

Le Moing, V

Longuet, P

Leport, C

Vildé, JL

Lamotte, C

Peytavin, G

Farinotti, R

机构：

[1] Hop Bichat Claude Bernard, Serv Malad Infect & Trop, F-75877 Paris, France

[2] Hop Bichat Claude Bernard, Serv Pharmacocinet Clin, F-75877 Paris, France

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2000年 / 44卷 / 09期

基金：

英国惠康基金;

关键词：

D O I：

10.1128/AAC.44.9.2593-2593.2000

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

引用

页码：2593 / 2593

页数：1

共 4 条

[1] Amprenavir [J].

Adkins, JC ;

Faulds, D .

DRUGS, 1998, 55 (06) :837-842

[2] Ritonavir - Clinical pharmacokinetics and interactions with other anti-HIV agents [J].

Hsu, A ;

Granneman, GR ;

Bertz, RJ .

CLINICAL PHARMACOKINETICS, 1998, 35 (04) :275-291

[3] WEAK BINDING OF VX-478 TO HUMAN PLASMA-PROTEINS AND IMPLICATIONS FOR ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS THERAPY [J].

LIVINGSTON, DJ ;

PAZHANISAMY, S ;

PORTER, DJT ;

PARTALEDIS, JA ;

TUNG, RD ;

PAINTER, GR .

JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (05) :1238-1245

[4] Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults [J].

Sadler, BM ;

Hanson, CD ;

Chittick, GE ;

Symonds, WT ;

Roskell, NS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) :1686-1692

← 1 →